Episode Details
Back to Episodes
Genetic Clues to Targeted CLL Treatments | Health and Fitness News
Description
When treating chronic lymphocytic leukemia, doctors don’t just rely on the diagnosis—they decode the cancer’s genetic blueprint to predict behavior and tailor treatments. Key biomarkers like IGHV mutation status, chromosome abnormalities, and TP53 mutations reveal whether the cancer is slow or aggressive, guiding decisions toward targeted therapies like BTK inhibitors or venetoclax instead of outdated chemo. Since CLL’s genetics can evolve over time, these tests are repeated at diagnosis and before treatment to ensure the plan stays precise and effective.
Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.
Advertise on DNN:
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.
View sources & latest updates:
https://sources.thednn.ai/0b0908a0516871f4